GlassScriptPhysician profile
Allison Bohne
NPI 1841687134
$2,101.44
in general payments reported to CMS, 2019-2025
15 companies · $796 in 2025
The $796 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $99.99 · 2023: $468 · 2024: $603 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $539.53 | 2021-2025 | |
| Novo Nordisk INC | $240.47 | 2023-2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.18 | 2023-2025 | Xifaxan |
| Janssen Biotech, INC. | $182.80 | 2024-2025 | Tremfya, Tecvayli, Darzalex |
| Inspire Medical Systems, INC. | $159.84 | 2025 | Inspire |
| Amgen INC. | $144.77 | 2025 | Tepezza |
| Viiv Healthcare Company | $124.74 | 2024 | Dovato |
| Jazz Pharmaceuticals INC. | $121.82 | 2025 | |
| Alnylam Pharmaceuticals INC. | $121.60 | 2023 | Amvuttra |
| Janssen Pharmaceuticals, INC | $99.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.40 | 2023 | |
| Janssen Scientific Affairs, LLC | $45.42 | 2025 | Tremfya |
| Globus Medical, INC. | $27.55 | 2025 | Senza |
| Genentech USA, INC. | $19.77 | 2021 | |
| Stryker Corporation | $14.56 | 2024 | Mako |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Bohne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.